Survodutide Phase 3 Trial SYNCHRONIZE-HERA Registered, Not Yet Recruiting

A Phase 3 clinical trial of survodutide was registered on ClinicalTrials.gov, with a record dated September 30, 2026. The trial is titled "SYNCHRONIZE-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight." It is listed under identifier NCT07850050. The trial status is currently Not Yet Recruiting. As a Phase 3 study, it represents a later stage in clinical development. No results have been posted for this trial at this time. Survodutide remains an unapproved compound under research and is not currently approved for any indication. The trial record does not indicate when recruitment is expected to begin. No outcome data, efficacy claims, or safety findings are included in this registration update. Readers should note that registration of a trial does not indicate results or conclusions about the compound's effects. For additional context on survodutide, including its regulatory status and research background, readers can consult the compound overview.